Stonepine Capital Management, LLC An2 Therapeutics, Inc. Transaction History
Stonepine Capital Management, LLC
- $123 Billion
- Q3 2025
A detailed history of Stonepine Capital Management, LLC transactions in An2 Therapeutics, Inc. stock. As of the latest transaction made, Stonepine Capital Management, LLC holds 563,913 shares of ANTX stock, worth $642,860. This represents 0.58% of its overall portfolio holdings.
Number of Shares
563,913
Previous 544,494
3.57%
Holding current value
$642,860
Previous $577 Million
24.08%
% of portfolio
0.58%
Previous 0.57%
Shares
3 transactions
Others Institutions Holding ANTX
# of Institutions
35Shares Held
7.57MCall Options Held
0Put Options Held
0-
Almitas Capital LLC Santa Monica, CA1.43MShares$1.63 Million0.85% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.08MShares$1.23 Million0.0% of portfolio
-
Peapod Lane Capital LLC Bedford Hills, NY589KShares$671,7060.67% of portfolio
-
Bank Of Nova Scotia459KShares$523,4810.0% of portfolio
-
Landscape Capital Management, L.L.C.456KShares$520,3670.04% of portfolio
About AN2 Therapeutics, Inc.
- Ticker ANTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 19,402,700
- Market Cap $22.1M
- Description
- AN2 Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for rare, chronic, and serious infectious diseases. It is developing epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial lung disease. The company was incorporated in 2017 and is headquartered in Menl...